Comparative Pharmacology
Head-to-head clinical analysis: AMOXIL versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXIL versus UNIPEN.
AMOXIL vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in CrCl <30 mL/min.
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic